Abstract
Receptor protein tyrosine phosphatases (RPTPs) are involved in many cellular processes, including the regulation of adhesion, migration and cellular signaling. Many RPTPs are putative tumor suppressors because of the transcriptional and translational changes observed in their expression during tumorigenesis. Recently, RPTPs were shown to be post-translationally regulated during tumorigenesis by proteolysis in a manner similar to proteolysis of the Notch receptor. There is accumulating evidence that proteolysis of RPTPs influence their cellular function and that RPTP fragments may function as oncogenes. By exploiting what is known about RPTP ligand binding domains and crystal structures of ligand-RPTP interfaces, we describe novel molecular diagnostics that have been or can be developed to identify tumor margins and target tumor tissues.
Keywords: Cell-cell interactions, cell-cell adhesion, receptor protein tyrosine phosphatase, RPTPs, cancer, Tumor-derived, Notch receptor, CAMs, Laminin/nidogen, ECD, ADAM
Anti-Cancer Agents in Medicinal Chemistry
Title: Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools
Volume: 11 Issue: 1
Author(s): Sonya E.L. Craig and Susann M. Brady-Kalnay
Affiliation:
Keywords: Cell-cell interactions, cell-cell adhesion, receptor protein tyrosine phosphatase, RPTPs, cancer, Tumor-derived, Notch receptor, CAMs, Laminin/nidogen, ECD, ADAM
Abstract: Receptor protein tyrosine phosphatases (RPTPs) are involved in many cellular processes, including the regulation of adhesion, migration and cellular signaling. Many RPTPs are putative tumor suppressors because of the transcriptional and translational changes observed in their expression during tumorigenesis. Recently, RPTPs were shown to be post-translationally regulated during tumorigenesis by proteolysis in a manner similar to proteolysis of the Notch receptor. There is accumulating evidence that proteolysis of RPTPs influence their cellular function and that RPTP fragments may function as oncogenes. By exploiting what is known about RPTP ligand binding domains and crystal structures of ligand-RPTP interfaces, we describe novel molecular diagnostics that have been or can be developed to identify tumor margins and target tumor tissues.
Export Options
About this article
Cite this article as:
E.L. Craig Sonya and M. Brady-Kalnay Susann, Tumor-Derived Extracellular Fragments of Receptor Protein Tyrosine Phosphatases (RPTPs) as Cancer Molecular Diagnostic Tools, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941244
DOI https://dx.doi.org/10.2174/187152011794941244 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Technological Maturity and Systematic Review of Medicinal Plants with Pharmacological Activity in the Central Nervous System
Recent Patents on Biotechnology Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Angiogenesis in Glioblastoma Multiforme: Navigating the Maze
Anti-Cancer Agents in Medicinal Chemistry Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Potential Therapeutic Application of Chondroitin Sulfate/Dermatan Sulfate
Current Drug Discovery Technologies Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Decorin Biology, Expression, Function and Therapy in the Cornea
Current Molecular Medicine Meet Our Editorial Board Member
Letters in Drug Design & Discovery Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets G-Protein Coupled Receptor Resensitization - Appreciating the Balancing Act of Receptor Function
Current Molecular Pharmacology Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy